Ark. judge affirms $181 million in legal fees

(AP)—An Arkansas judge says Johnson & Johnson must pay $181 million in fees to attorneys who successfully argued that the pharmaceutical company committed Medicaid fraud in the marketing of its antipsychotic drug Risperdal.

Pulaski County Tim Fox ruled Thursday that Arkansas taxpayers should not foot the bill in the lawsuit filed by the state's attorney general. Last year, a jury found that Johnson & Johnson, through its Janssen Pharmaceuticals subsidiary, had committed Medicaid fraud and violated the state's deceptive trade practices act.

Johnson & Johnson had argued that legal fees of $2.2 million to $3.8 million would be appropriate. A Janssen spokeswoman tells the Arkansas Democrat-Gazette (is.gd/Qf85x4 ) that the company maintains it did not violate the state's Medicaid fraud law and that no legal fees should have been ordered.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Report: J&J will pay $2.2B in Risperdal settlement

Jul 20, 2012

(AP) — Johnson & Johnson has agreed to pay as much as $2.2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal, according to a published report.

Merck pays J&J $500mn in drug row settlement

Apr 15, 2011

Merck said Friday it has agreed to pay fellow US pharmaceutical giant Johnson & Johnson $500 million to end a two-year tussle over profit-sharing deals for two anti-inflammatory drugs.

Danish Genmab inks $1.1 bn deal with Johnson & Johnson

Aug 30, 2012

Danish pharmaceutical group Genmab said Thursday it had reached a deal worth up to $1.1 billion (876 million euros) with US drug giant Johnson & Johnson for the rights to the cancer treatment Daratumumab.

Johnson & Johnson plans to buy Dutch vaccine group

Sep 17, 2010

US cosmetics and pharmaceutical giant Johnson & Johnson said on Friday it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about 1.75 billion euros.

Public Citizen: State drug fraud cases on the rise

Sep 27, 2012

(AP)—A consumer advocacy group is reporting that pharmaceutical companies have paid more than $30 billion to state and federal governments to settle allegations of fraud over the last 20 years.

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments